SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 222 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $307,929 | -9.7% | 11,169 | -1.5% | 0.00% | 0.0% |
| Q2 2023 | $340,850 | -15.0% | 11,339 | +2.5% | 0.00% | 0.0% |
| Q1 2023 | $400,776 | -9.6% | 11,062 | -11.0% | 0.00% | -50.0% |
| Q4 2022 | $443,342 | +15.5% | 12,429 | +9.4% | 0.00% | +100.0% |
| Q3 2022 | $384,000 | +18.9% | 11,361 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $323,000 | -39.7% | 11,197 | -32.4% | 0.00% | 0.0% |
| Q1 2022 | $536,000 | -7.3% | 16,567 | -16.6% | 0.00% | 0.0% |
| Q4 2021 | $578,000 | +14.0% | 19,862 | +4.4% | 0.00% | 0.0% |
| Q3 2021 | $507,000 | -30.5% | 19,019 | -19.8% | 0.00% | -50.0% |
| Q2 2021 | $730,000 | +27.4% | 23,713 | +8.3% | 0.00% | 0.0% |
| Q1 2021 | $573,000 | +14.1% | 21,891 | +9.7% | 0.00% | 0.0% |
| Q4 2020 | $502,000 | +56.4% | 19,947 | +29.4% | 0.00% | +100.0% |
| Q3 2020 | $321,000 | -15.1% | 15,418 | -3.1% | 0.00% | -50.0% |
| Q2 2020 | $378,000 | +91.9% | 15,904 | +45.1% | 0.00% | +100.0% |
| Q1 2020 | $197,000 | -57.4% | 10,962 | -43.7% | 0.00% | -50.0% |
| Q4 2019 | $462,000 | -20.5% | 19,466 | -7.9% | 0.00% | -33.3% |
| Q3 2019 | $581,000 | -20.1% | 21,141 | -3.8% | 0.00% | -25.0% |
| Q2 2019 | $727,000 | -15.6% | 21,979 | -10.6% | 0.00% | -20.0% |
| Q1 2019 | $861,000 | +6.6% | 24,583 | +1.0% | 0.01% | -16.7% |
| Q4 2018 | $808,000 | -43.9% | 24,337 | -14.9% | 0.01% | -40.0% |
| Q3 2018 | $1,440,000 | -19.5% | 28,602 | -4.3% | 0.01% | -16.7% |
| Q2 2018 | $1,789,000 | +24.1% | 29,888 | -5.0% | 0.01% | +33.3% |
| Q1 2018 | $1,441,000 | -0.5% | 31,473 | -13.4% | 0.01% | -10.0% |
| Q4 2017 | $1,448,000 | +10.4% | 36,344 | +10.8% | 0.01% | -16.7% |
| Q3 2017 | $1,312,000 | -1.0% | 32,802 | +6.7% | 0.01% | -7.7% |
| Q2 2017 | $1,325,000 | +27.0% | 30,747 | -7.7% | 0.01% | +18.2% |
| Q1 2017 | $1,043,000 | -0.1% | 33,319 | -19.4% | 0.01% | -8.3% |
| Q4 2016 | $1,044,000 | +12.5% | 41,344 | +10.2% | 0.01% | -7.7% |
| Q3 2016 | $928,000 | +5.2% | 37,508 | -13.4% | 0.01% | +18.2% |
| Q2 2016 | $882,000 | +40.4% | 43,300 | +5.1% | 0.01% | +22.2% |
| Q1 2016 | $628,000 | +3.5% | 41,204 | -8.8% | 0.01% | +28.6% |
| Q4 2015 | $607,000 | +5.9% | 45,196 | +10.6% | 0.01% | -12.5% |
| Q3 2015 | $573,000 | -21.5% | 40,864 | -5.0% | 0.01% | -20.0% |
| Q2 2015 | $730,000 | +49.9% | 43,017 | +6.9% | 0.01% | +66.7% |
| Q1 2015 | $487,000 | +69.1% | 40,243 | +15.9% | 0.01% | +100.0% |
| Q4 2014 | $288,000 | -1.7% | 34,719 | +2.9% | 0.00% | -25.0% |
| Q3 2014 | $293,000 | -32.8% | 33,746 | -15.2% | 0.00% | -33.3% |
| Q2 2014 | $436,000 | +15.0% | 39,797 | -6.1% | 0.01% | +20.0% |
| Q1 2014 | $379,000 | +213.2% | 42,378 | +164.0% | 0.01% | +150.0% |
| Q4 2013 | $121,000 | -18.8% | 16,051 | -20.8% | 0.00% | -50.0% |
| Q3 2013 | $149,000 | – | 20,271 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |